Fulcrum Therapeutics
The Director of Analytical Chemistry at Fulcrum Therapeutics leads the design and execution of control strategies for drug substance and drug product manufacturing. The role involves providing technical oversight of QC activities at contract manufacturers and collaborating with cross-functional teams on regulatory filings.
Headquarters
Cambridge, Massachusetts, United States
Company Size
51-200 employees
Founded
2016
Fulcrum Therapeutics is a clinical‑stage biotechnology company that discovers and develops small molecules to modulate gene expression and address the root causes of genetically defined diseases. Their approach focuses on transcriptional regulation and restoring healthy gene programs through genetics‑driven target identification and proprietary discovery platforms. Fulcrum advances a pipeline of precision medicines across genetically defined indications while emphasizing translational science, patient impact, and a collaborative organizational culture.
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC
15 hours ago
Boothbay Fund Management Increases Stake in Fulcrum Therapeutics
14 hours ago
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Fulcrum Therapeutics.
17% above the average for this role
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
3 weeks ago
Sickle cell drug from Fulcrum lifts fetal hemoglobin 12.2% in early trial data
3 weeks ago